Viracta Therapeutics Newsroom

Viracta Therapeutics Is Maintained at Outperform by RBC Capital

Dow JonesNov 14 12:18 ET

Viracta Therapeutics Analyst Ratings

BenzingaNov 14 12:10 ET

RBC Cuts Price Target on Viracta Therapeutics to $2 From $4, Keeps Outperform, Speculative Risk

MT NewswiresNov 14 07:42 ET

Viracta Therapeutics Analyst Ratings

BenzingaAug 15 10:55 ET

RBC Adjusts Price Target on Viracta Therapeutics to $4 From $6, Maintains Outperform

MT NewswiresAug 15 08:47 ET

Viracta Therapeutics Analyst Ratings

BenzingaMay 23 08:24 ET

Oppenheimer Keeps Their Buy Rating on Viracta Therapeutics (VIRX)

TipRanksMay 23 07:55 ET

Viracta Therapeutics Analyst Ratings

BenzingaApr 17 08:50 ET

Analysts Offer Insights on Healthcare Companies: Viracta Therapeutics (VIRX) and UnitedHealth (UNH)

TipRanksApr 17 07:55 ET

Viracta Therapeutics Analyst Ratings

BenzingaApr 16 10:44 ET

Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)

TipRanksApr 16 06:35 ET

Buy Rating for Viracta Therapeutics Backed by Upcoming Catalysts and Solid Financials

TipRanksMar 12 06:30 ET

Viracta Therapeutics Analyst Ratings

BenzingaMar 12 06:21 ET

Analysts Are Bullish on These Healthcare Stocks: ITeos Therapeutics (ITOS), Viracta Therapeutics (VIRX)

TipRanksMar 11 00:55 ET

RBC Capital Sticks to Its Buy Rating for Viracta Therapeutics (VIRX)

TipRanksMar 8 07:31 ET

HC Wainwright & Co. Maintains Buy on Viracta Therapeutics, Lowers Price Target to $4

BenzingaJan 5 06:17 ET

Viracta Therapeutics Analyst Ratings

BenzingaJan 5 06:17 ET

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Viracta Therapeutics (VIRX) and Gossamer Bio (GOSS)

TipRanksNov 14, 2023 03:30 ET

RBC Capital Maintains Outperform on Viracta Therapeutics, Lowers Price Target to $6

BenzingaNov 10, 2023 14:33 ET

Viracta Therapeutics Analyst Ratings

BenzingaNov 10, 2023 14:32 ET